RNAi-mediated Rab5a suppression inhibits proliferation and migration of vascular smooth muscle cells
暂无分享,去创建一个
Hao Wang | Duan Ma | Zongyou Chen | Duan Ma | Zongyou Chen | Hao Wang | Lei Zhu | Liang Wu | Zhigang Ma | Liang Wu | Lei Zhu | Weihao Shi | Bo Yu | W. Shi | Bo Yu | Zhi-Gang Ma
[1] U. Laufs,et al. Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.
[2] H. Feng,et al. Over-expression of the RAB5 gene in human lung adenocarcinoma cells with high metastatic potential. , 1999, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.
[3] G. Owens,et al. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. , 2000, The Journal of clinical investigation.
[4] E. Raines,et al. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease , 2000, International journal of experimental pathology.
[5] B. Berk,et al. Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells , 2006, Circulation research.
[6] M. Rogers,et al. Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] L. Machesky,et al. Rab5 and Rac Team Up in Cell Motility , 2008, Cell.
[8] Yingjin Yuan,et al. Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. , 2004, European journal of pharmacology.
[9] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[10] N. Hayashi,et al. Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[11] M. Davies,et al. Pathobiology of intimal hyperplasia , 1994, The British journal of surgery.
[12] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[13] E. Pieterman,et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.
[14] Kai Simons,et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway , 1992, Cell.
[15] G. Owens,et al. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.
[16] Duan Ma,et al. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. , 2009, European journal of pharmacology.
[17] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[18] W. Weintraub. The pathophysiology and burden of restenosis. , 2007, The American journal of cardiology.
[19] Giulio Gabbiani,et al. Arterial Smooth Muscle Cell Heterogeneity: Implications for Atherosclerosis and Restenosis Development , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[20] K. Karsch,et al. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.
[21] P. Delafontaine. Growth factors and vascular smooth muscle cell growth responses. , 1998, European heart journal.
[22] R. Ross. Cellular and molecular studies of atherogenesis. , 1997, Atherosclerosis.
[23] P. Stahl,et al. Evidence for a Symmetrical Requirement for Rab5-GTP in in Vitro Endosome-Endosome Fusion* , 1998, The Journal of Biological Chemistry.
[24] P. Serruys,et al. Drug-Eluting Stent Update 2007: Part II: Unsettled Issues , 2007, Circulation.
[25] A. Schmidt,et al. Differentiation of coronary smooth muscle cells to a cell cycle-arrested hypertrophic growth status by a synthetic non-toxic heparin-mimicking compound. , 1999, Atherosclerosis.
[26] M. Böhm,et al. Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in Swine , 2007, Investigative radiology.
[27] P. Robinson,et al. The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. , 2007, Biochimica et biophysica acta.
[28] A. Llorente,et al. Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. , 2007, European journal of cell biology.
[29] A. Wells,et al. Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. , 2000 .
[30] W. Seeger,et al. Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus &agr;-Toxin , 2002, Circulation.
[31] U. Laufs,et al. Targeting Rho in cardiovascular disease. , 2000, Circulation research.